Sartorius Stedim Biotech (DIM) AGM 2025 summary

Opening remarks and agenda

• Chairman welcomed shareholders, introduced board members, and outlined the meeting's structure, including extraordinary and ordinary sessions with live webcast access.

• Officers and scrutineers were appointed, and the quorum was confirmed at 94.96%.

• Agenda included reading reports from the Board of Directors and Statutory Auditors, and voting on resolutions in both extraordinary and ordinary sessions.

• Agenda and resolutions were made available in advance and at the meeting.

Board and executive committee updates

• Proposed renewal of mandates for four directors and appointment of two new board members, Cécile Dussart and Chris Nowers, both with extensive biopharma and cell therapy experience.

• Henri Riey retired from the board after long service.

• Board included both executive and non-executive members, emphasizing independence and diversity in nationality.

Financial performance review

• 2024 sales reached €2.8 billion, a 1% increase year-over-year and 93% growth over five years.

• EBITDA margin at 28%, with 85% EBITDA growth since 2019.

• Order intake grew by 13% in constant currencies, with significant business momentum in the final quarter.

• Efficiency programs delivered over €85 million in savings, and 3,700 new jobs were added over five years.